mecamylamine has been researched along with Depression in 13 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared smokers with schizophrenia (SS; n=27) and control smokers (CS; n=26) on smoking and psychiatric outcomes at baseline, during acute smoking abstinence and reinstatement, and with pre-treatment using the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (MEC) in a human laboratory setting." | 9.12 | Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. ( Creeden, CL; George, TP; Jatlow, PI; Sacco, KA; Vessicchio, JC; Weinberger, AH, 2007) |
| " We compared smokers with schizophrenia (SS; n=27) and control smokers (CS; n=26) on smoking and psychiatric outcomes at baseline, during acute smoking abstinence and reinstatement, and with pre-treatment using the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine (MEC) in a human laboratory setting." | 5.12 | Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. ( Creeden, CL; George, TP; Jatlow, PI; Sacco, KA; Vessicchio, JC; Weinberger, AH, 2007) |
| " To limit the potential adverse effects of alteration in cholinergic and nitric oxide (NO) systems, we investigated the combined efficacy of subthreshold doses of nAChR antagonist mecamylamine and NO ligands (L-arginine as agonist and l-NAME as an antagonist) on depression- and anxiety-related behaviors in male NMRI mice." | 3.96 | Better antidepressant efficacy of mecamylamine in combination with L-NAME than with L-arginine. ( Ebrahimi-Ghiri, M; Mohammadi-Mahdiabadi-Hasani, MH; Nasehi, M; Zarrindast, MR, 2020) |
| " All mice were then, 96 hr later, challenged with mecamylamine (3 mg/kg), and tested for anxiety-like behaviors 30 min later." | 3.96 | The role of pituitary adenylyl cyclase activating polypeptide in affective signs of nicotine withdrawal. ( Ahmad, SM; Hamid, A; Lutfy, K; Marquez, P; Nega, S, 2020) |
| "The symptom of "diminished interest or pleasure" in rewarding stimuli is an affective symptom of nicotine and amphetamine withdrawal, and a core symptom of depression." | 3.71 | Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. ( Harrison, AA; Liem, YT; Markou, A, 2001) |
| "Antidepressant effects of acute or chronic nicotine treatments in swim test immobility of Flinders sensitive line (FSL) rats, an animal model of depression, were recently demonstrated (Tizabi et al." | 3.70 | Depressive characteristics of FSL rats: involvement of central nicotinic receptors. ( Overstreet, DH; Rezvani1, AH; Russell, LT; Tizabi, Y; Tyler, KY, 2000) |
| "Epidemiological studies of smokers suggest that there is a link between nicotine and depression." | 3.70 | Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. ( Brodkin, JD; Ferguson, SM; Lloyd, GK; Menzaghi, F, 2000) |
| "Primary efficacy measures included the Tourette's Disorder Scale-Clinician Rated (TODS-CR) and 21-point Clinical Global Improvement scale; secondary efficacy measures included the Yale Global Tic Severity Scale and a rage-attack scale (RAScal)." | 2.70 | Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder. ( Ramos, A; Sanberg, PR; Sheehan, DV; Sheehan, KH; Shytle, RD; Silver, AA, 2001) |
| " Impaired neurogenesis observed in OBX mice was significantly improved by chronic administration with ZSET1446." | 1.36 | A novel cognitive enhancer, ZSET1446/ST101, promotes hippocampal neurogenesis and ameliorates depressive behavior in olfactory bulbectomized mice. ( Fukunaga, K; Han, F; Hino, M; Moriguchi, S; Shioda, N; Yamaguchi, Y; Yamamoto, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ebrahimi-Ghiri, M | 1 |
| Mohammadi-Mahdiabadi-Hasani, MH | 1 |
| Nasehi, M | 1 |
| Zarrindast, MR | 1 |
| Nega, S | 1 |
| Marquez, P | 1 |
| Hamid, A | 1 |
| Ahmad, SM | 1 |
| Lutfy, K | 1 |
| Shioda, N | 1 |
| Yamamoto, Y | 1 |
| Han, F | 1 |
| Moriguchi, S | 1 |
| Yamaguchi, Y | 1 |
| Hino, M | 1 |
| Fukunaga, K | 1 |
| Ledford, H | 1 |
| Sanberg, PR | 2 |
| Vindrola-Padros, C | 1 |
| Shytle, RD | 2 |
| BHARGAVA, KP | 1 |
| DHAWAN, KN | 1 |
| MEIRING, PD | 1 |
| Weinberger, AH | 1 |
| Sacco, KA | 1 |
| Creeden, CL | 1 |
| Vessicchio, JC | 1 |
| Jatlow, PI | 1 |
| George, TP | 1 |
| Mineur, YS | 1 |
| Somenzi, O | 1 |
| Picciotto, MR | 1 |
| Tizabi, Y | 1 |
| Rezvani1, AH | 1 |
| Russell, LT | 1 |
| Tyler, KY | 1 |
| Overstreet, DH | 1 |
| Ferguson, SM | 1 |
| Brodkin, JD | 1 |
| Lloyd, GK | 1 |
| Menzaghi, F | 1 |
| Harrison, AA | 1 |
| Liem, YT | 1 |
| Markou, A | 1 |
| Silver, AA | 1 |
| Sheehan, KH | 1 |
| Sheehan, DV | 1 |
| Ramos, A | 1 |
1 review available for mecamylamine and Depression
| Article | Year |
|---|---|
Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.
Topics: Animals; Basal Ganglia; Depression; Humans; Mecamylamine; Nicotine; Tourette Syndrome; Translational | 2012 |
2 trials available for mecamylamine and Depression
| Article | Year |
|---|---|
Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia.
Topics: Acute Disease; Adult; Cotinine; Demography; Depression; Female; Humans; Male; Mecamylamine; Nicotine | 2007 |
Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder.
Topics: Adolescent; Child; Comorbidity; Depression; Double-Blind Method; Female; Ganglionic Blockers; Heart | 2001 |
10 other studies available for mecamylamine and Depression
| Article | Year |
|---|---|
Better antidepressant efficacy of mecamylamine in combination with L-NAME than with L-arginine.
Topics: Animals; Animals, Outbred Strains; Antidepressive Agents; Anxiety; Arginine; Behavior, Animal; Choli | 2020 |
The role of pituitary adenylyl cyclase activating polypeptide in affective signs of nicotine withdrawal.
Topics: Animals; Anxiety; Conditioning, Psychological; Depression; Female; Male; Mecamylamine; Mice; Mice, I | 2020 |
A novel cognitive enhancer, ZSET1446/ST101, promotes hippocampal neurogenesis and ameliorates depressive behavior in olfactory bulbectomized mice.
Topics: Animals; Behavior, Animal; Dentate Gyrus; Depression; Dose-Response Relationship, Drug; Extracellula | 2010 |
Depression drug disappoints.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Humans; Mecamylamine; Stereo | 2011 |
DEPRESSION OF THE VASOMOTOR CENTRE BY MECAMYLAMINE, INDEPENDENT OF ITS GANGLION-BLOCKING ACTIVITY.
Topics: Acetylcholine; Animals; Cats; Central Nervous System; Depression; Depressive Disorder; Dogs; Ganglia | 1963 |
EXPERIENCES WITH THE LONG-TERM USE OF METHYLDOPA ("ALDOMET") IN HYPERTENSION.
Topics: Benzothiadiazines; Blood Pressure Determination; Depression; Drug Therapy; Drug Tolerance; Glomerulo | 1965 |
Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice.
Topics: Alkaloids; Animals; Antidepressive Agents; Anxiety; Azocines; Brain; Depression; Feeding Behavior; G | 2007 |
Depressive characteristics of FSL rats: involvement of central nicotinic receptors.
Topics: Alkaloids; Animals; Antidepressive Agents; Azocines; Depression; Male; Mecamylamine; Nicotine; Quino | 2000 |
Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Depression; Dose-Response Relationship, Drug; Im | 2000 |
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Topics: Aminopyridines; Amphetamine; Amphetamine-Related Disorders; Animals; Body Weight; Brain; Depression; | 2001 |